Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript
Inspire Medical Systems (NYSE:INSP) reported Q2 2026 revenue of $200.6M, down 7.6% year over year, citing coding and reimbursement disruptions. Adjusted diluted EPS was $0.14 versus $0.34 a year earlier. Gross margin rose to 85.5%. Full-year revenue guidance was raised to $835M-$875M, with an estimated $40M Q2 and $120M-$130M full-year reimbursement headwind.
How this was made
The 30-second read
Why it matters
Key trading inputs are the raised full-year revenue guidance, quantified coding and reimbursement adverse impact, third-quarter revenue decline forecast, and updated operating margin guidance, all tied to payer processing and CMS reimbursement proposals.
Market read
Traders can update INSP’s near-term earnings expectations using the explicit Q3 revenue decline forecast and the quantified reimbursement drag, while also factoring the guidance raise and CMS 2027 rate proposals into longer-horizon demand and reimbursement assumptions.
What to watch
The call flags MAC-specific modifier requirements and regional payment reductions (0% to 30% of national average), which could create uneven center-level adoption and revenue volatility beyond the headline guidance.
Background
This is a Q2 2026 earnings call transcript covering revenue, EPS, margin, and detailed reimbursement and coding headwinds for Inspire V, plus Project Horizon restructuring and supply-chain consolidation.
Ticker impact
Inspire raised full-year 2026 revenue guidance to $835M-$875M while estimating $40M Q2 coding and reimbursement headwinds and $120M-$130M full-year impact.
Likely choppy reaction: upside from raised revenue outlook and CMS 2027 facility/ASC reimbursement proposals, offset by weaker Q3 revenue forecast and sizable coding/reimbursement drag.
The article provides multiple forward-looking datapoints (raised FY revenue range, Q3 decline forecast, margin guidance, and quantified reimbursement impacts) that directly affect INSP’s near-term earnings power and demand conversion assumptions.
Market effects
Reinforces that neurostimulation device makers’ near-term performance is highly sensitive to Medicare coding/modifier rules and payer prior authorization workflows.
Highlights Continental Europe growth (Germany) and France reimbursement changes as a potential offset to US coding disruptions.
CMS-proposed 2027 reimbursement rates may influence broader US outpatient and ASC reimbursement expectations for similar implantable therapies.
Counterpoint
The raised FY revenue range may not translate into earnings durability if the $120M-$130M full-year reimbursement impact and Q3 revenue decline drive continued operating leverage pressure.
Key entities
- companyInspire Medical Systems, Inc.
NYSE-listed neurostimulation device maker providing Q2 results and updated 2026 guidance amid coding and reimbursement disruptions.
- regulatorCMS
US Centers for Medicare and Medicaid Services, whose proposed 2027 reimbursement rates are cited as supportive for facility and ASC reimbursement.
- payer/administratorMACs
Medicare Administrative Contractors referenced for modifier requirements that drive regional physician reimbursement headwinds.
